Skip to main content
SpringerLink
Log in

Radionuclide Therapy of Bone Metastases with Radium-223 Chloride in Prostate Cancer Patients

  • Chapter
  • First Online:
Clinical Nuclear Medicine

  • 1353 Accesses

Abstract

Radium-223 chloride can prolong survival and improve quality of life in symptomatic, castration-resistant prostate cancer patients. It should be restricted to patients without visceral metastases (lymph node metastases excluded) having received two systemic second-line treatments. As a monotherapy before or after chemotherapy, radium-223 has a favourable safety profile.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grünwald F, Knapp F.F, Biersack HJ. Dose escalation study with rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000;27:123–130.

    Google Scholar 

  2. Hillner BE, et al. American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378–91.

    Article  CAS  Google Scholar 

  3. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23(31):7904–10.

    Article  CAS  Google Scholar 

  4. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  Google Scholar 

  5. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.

    Article  CAS  Google Scholar 

  6. Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Krebs D, Risse J, Biersack HJ. Pain palliation with Rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med. 1999;24:643–8.

    Article  CAS  Google Scholar 

  7. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21(15):2869–75.

    Article  CAS  Google Scholar 

  8. Tu S, Millikan RE, Mengistu B, et al. Bone targeted therapy for advanced androgen-imdependent carcinoma of the prostate: randomised phase II trial. Lancet. 2001;357:336–41.

    Article  CAS  Google Scholar 

  9. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms 2. Aktualisierung – Oktober 2014 AWMF-Register-Nummer 043/022OL.

    Google Scholar 

  10. European guideline, prostate cancer.

    Google Scholar 

  11. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.

    Google Scholar 

  12. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using Samarium-153 lexidronam: a double blind placebo-controlled trial. J Clin Oncol. 1998;16:1574–81.

    Article  CAS  Google Scholar 

  13. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.

    Article  CAS  Google Scholar 

  14. Lassmann et al Eur J Nucl Med Mol Imaging 2013;40:207.

    Google Scholar 

  15. Carrasquillo Eur J Nucl Med Mol Imaging 2013 EJNM 2013.

    Google Scholar 

  16. Clin Canc Res 2005:11;4451.

    Google Scholar 

  17. Hobbs RF et al. Phys Med Biol 2012 3207–3222.

    Google Scholar 

  18. Ritter MA, et al. Nature. 1977;266:5603.

    Article  Google Scholar 

  19. Bruland OS, et al. Clin Cancer Res. 2006;12:6250.

    Article  Google Scholar 

  20. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, Vorreuther R, Göhring U, Schild HH, Gerhardt T, Pöge U, Ezziddin S, Biersack HJ, Ahmadzadehfar H. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.

    Article  CAS  Google Scholar 

  21. Palmedo H, Eschmann S, Werner A, Selinski I, Möllers MO, Pinkert J, van Crüchten I Neußer T, Pöppel T. First interim analysis of PARABO – a non-interventional study evaluating mCRPC patients with bone metastases treated with radium-223 in a real life german practice setting. Abstract march 2018 European Association of Urology, Kopenhagen.

    Google Scholar 

  22. Parker C, Finkelstein SE, Michalski JM, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70:875–83.

    Article  CAS  Google Scholar 

  23. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J. O'Sullivan JM; Radium-223 international early access program investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16.

    CAS  Google Scholar 

  24. Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406.

    Article  CAS  Google Scholar 

  25. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868–74.

    Article  CAS  Google Scholar 

  26. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. Eur Urol. 73(3):427–35.

    Article  Google Scholar 

  27. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, Ezziddin S, Bucerius J, von Mallek D. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52(11):1721.

    Article  CAS  Google Scholar 

  28. Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(5):824–45.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Radiology and Nuclear Medicine in der Kaiser-Passage Bonn, PET-CT Center, Clinical Cancer Center Johanniter Hospital, Bonn, Germany

    Holger Palmedo

Authors
  1. Holger Palmedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Klinikum Westfalen - Knappschaftskrankenhaus Academic teaching hospital of the Ruhr University, Dortmund, Nordrhein-Westfalen, Germany

    Hojjat Ahmadzadehfar

  2. Department of Nuclear Medicine, Beta Klinik Bonn, Bonn, Germany

    Hans-Jürgen Biersack

  3. Division of Nuclear Medicine, Department of Radiology, Montefiore Medical Center, Bronx, NY, USA

    Leonard M. Freeman

  4. Albert Einstein College of Medicine, Bronx, NY, USA

    Lionel S. Zuckier

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Palmedo, H. (2020). Radionuclide Therapy of Bone Metastases with Radium-223 Chloride in Prostate Cancer Patients. In: Ahmadzadehfar, H., Biersack, HJ., Freeman, L., Zuckier, L. (eds) Clinical Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-39457-8_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-39457-8_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-39455-4

  • Online ISBN: 978-3-030-39457-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation